-transparent.png){kind=logo}
Malaria is one of the major global health problems, and an urgent need for the development of new antimalarial agents faces the scientific community. A considerable number of iron(III) chelators, designed for purposes other than treating malaria, have antimalarial activity in vitro, apparently through the mechanism of withholding iron from vital metabolic pathways of the intra-erythrocytic parasite. Certain iron(II) chelators also have antimalarial activity, but the mechanism of action appears to be the formation of toxic complexes with iron rather than the withholding of iron. Several of the iron(III)-chelating compounds also have antimalarial activity in animal models of plasmodial infection. Iron chelation therapy with desferrioxamine, the only compound of this nature that is widely available for use in humans, has clinical activity in both uncomplicated and severe malaria in humans.
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
January 1994,
Advances in experimental medicine and biology,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
February 1993,
The American journal of tropical medicine and hygiene,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
May 1980,
Nutrition reviews,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
March 2007,
Current gastroenterology reports,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
September 1979,
British journal of haematology,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
March 2005,
Current hematology reports,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
March 1995,
Current opinion in hematology,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
May 2023,
European journal of haematology,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
January 1997,
Journal of internal medicine. Supplement,
G F Mabeza, and
M Loyevsky, and
V R Gordeuk, and
G Weiss
February 2020,
Clinical and experimental medicine,
